CD8A and granular corneal dystrophy type II: Together, these data support that different cytokines, transcription factors, and surface receptors involved in CD8+ TRM cell development and persistence could be targets in future treatment of rapid-onset ACD and other CD8+ TRM cell-driven skin diseases.